Side Effects·5 min read

SS-31 Side Effects: Elamipretide Trial Data

Injection-site reactions lead. GI changes follow. Full safety breakdown from primary mitochondrial myopathy Phase 2/3 trials.

Save

SS-31 elamipretide side effects from clinical trials

SS-31 — elamipretide — has the strongest trial safety dataset of any community-discussed mitochondrial-targeted peptide. The MMPOWER trial series (Phase 2 and Phase 3 in primary mitochondrial myopathy) and the TAZPOWER Barth syndrome program produced multi-month adverse-event data in clinical doses. Injection-site reactions dominate the trial-reported event picture; the mechanism (cardiolipin binding in the inner mitochondrial membrane, characterized in PMID 32554501) is otherwise broadly protective.

Research-context information only. SS-31 (elamipretide) is FDA-approved for Barth syndrome under a specific brand-named product; research-peptide and compounded forms for other uses are not FDA-approved. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

This article summarizes the trial-reported adverse events, separates Phase 2/3 data from community self-reports, and walks through the dose-pause patterns described in protocols and community sources.

Trial-Reported Adverse Events

From the MMPOWER-2 and MMPOWER-3 trials and the TAZPOWER Barth syndrome trial:

Event Elamipretide Placebo Source
Any injection-site reaction (MMPOWER-2, n = 30 crossover) 80% — (elamipretide arm reported) Karaa et al., PMID 32096613
Injection-site erythema (TAZPOWER part 1, n = 12 crossover) 100% 25% Reid Thompson et al., PMID 33077895
Injection-site pain (TAZPOWER part 1) 75% 33% Reid Thompson et al., PMID 33077895
Injection-site pruritus (TAZPOWER part 1) 67% 17% Reid Thompson et al., PMID 33077895
Headache (TAZPOWER part 1) 8% 25% Reid Thompson et al., PMID 33077895
Nausea (TAZPOWER part 1) 8% 8% Reid Thompson et al., PMID 33077895
Discontinuation due to AEs (MMPOWER-3, n = 218) 7.3% 1.8% Karaa et al., PMID 37268435
Serious AEs (MMPOWER-3; none deemed treatment-related) 4.6% 2.8% Karaa et al., PMID 37268435

The MMPOWER-3 Phase 3 trial did not meet its primary efficacy endpoint, but the safety dataset was extensive and remains the most informative source for the adverse-event picture. The TAZPOWER program in Barth syndrome supported the September 2025 FDA approval.

CategoryLongevity & Mitochondrial Peptides
Classmitochondrial
GoalLongevity
Ss 31 research kit
Best Kit Deal10-VialCOASave 36%

Ion Peptide — 50mg × 10 (500mg) — $1043 $886 with code thepeptidecatalog (15% off) ($1.77/mg)

Top SS-31 (Elamipretide) Vendors

Ranked by price, COA availability, and reputation

1
Ascension PeptidesCOA
10/10
10mg$8.00/mg
2
Ion PeptideCOA
9.5/10
$4.50/mg
3
Glacier AminosCOA
9/10
10mg$3.45/mg
See full vendor rankings for SS-31 (Elamipretide) →

Injection-Site Reactions Are the Defining Event

Across trial reports, injection-site events (erythema, induration, pruritus, pain, hemorrhage) were collectively the most frequent adverse event. The pattern aligns with what published mechanism work would predict for a daily subcutaneous peptide: cumulative local tissue exposure produces local responses, while systemic events stay low.

Trial protocols recommended site rotation across abdomen, thigh, and upper arm. The MMPOWER-2 and MMPOWER-3 reports describe most injection-site events as mild to moderate (Karaa et al., PMID 32096613; PMID 37268435).

SS-31 trial adverse event frequencies

Cardiovascular and Systemic Safety

Trial monitoring across MMPOWER-2, MMPOWER-3, and TAZPOWER did not identify cardiovascular safety signals at rates above placebo. ECG monitoring, vital signs, and serum chemistry tracked across the trials showed no clinically significant changes attributable to elamipretide.

Mechanism research (PMID 32554501) describes elamipretide binding to cardiolipin in the inner mitochondrial membrane. Cardiolipin stabilization in cardiac mitochondria is broadly protective in preclinical models, which aligns with the absent cardiovascular adverse-event signal in trial monitoring.

Self-Reported Community Adverse Events

Note on labeling: the events below come from r/peptides, r/PeptideTherapy, and peptide forums for research-peptide and compounded SS-31 use outside the FDA-approved Barth indication. They overlap with but do not perfectly mirror trial findings.

The most consistent community feedback overlaps with the trial pattern:

  • Injection-site reactions — community sources describe approximately the same dominance as trials. Site rotation, smaller volumes per site, and bringing the vial to room temperature are the most-cited mitigation strategies.
  • Headache during the first week — sometimes attributed by community sources to vasodilatory effects.
  • Brief fatigue or "muted" feeling in the first 1-3 doses — fades by week 2 in most reports.
  • Sleep changes — mixed reports; some users describe deeper sleep, others describe early-morning waking.

Community sources occasionally describe transient brain-fog reduction in the first 2-3 weeks at higher doses, consistent with the peptide's mitochondrial-targeting mechanism. This is not characterized in published trial efficacy data outside the mitochondrial myopathy and Barth indications.

Less Common Trial-Reported Events

These appeared in trial datasets at low frequency.

  • Hypersensitivity reactions — sparse; trial protocols included dose-interruption rules for severe hypersensitivity.
  • Lab abnormalities — no consistent pattern of clinically significant changes in liver enzymes, renal function, or hematology.
  • Falls / motor events — reported in the MMPOWER mitochondrial myopathy population at rates consistent with the underlying disease, not attributed to elamipretide.

Dose-Response Patterns Documented in Research

The MMPOWER program tested 40 mg/day subcutaneous in adults; TAZPOWER tested 40 mg/day in adolescents and adults. Phase 2 dose-finding work explored 4-40 mg/day. The injection-site event rate scaled with daily dose in the dose-finding data; severe events did not.

Community-reported research-peptide doses cluster around 5-10 mg per dose, 5x weekly, which is below the trial daily dose. Self-reported community sources describe injection-site reaction rates lower than what trials report at 40 mg/day, consistent with the dose-effect relationship.

Bacteriostatic water vial — 0.9% benzyl alcohol multi-dose
Bac Water Made for Peptides
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
Shop bac water made for peptides

Dose-Pause and Discontinuation Patterns

Phase 2 and Phase 3 protocols allowed dose-interruption for severe injection-site reactions, persistent GI symptoms, or protocol-defined laboratory abnormalities. In MMPOWER-3, adverse events led to discontinuation in 7.3% of elamipretide participants versus 1.8% on placebo (Karaa et al., PMID 37268435).

Community sources describe two patterns. Pause-and-resume — short 3-5 day breaks when site reactions become persistent. Dose reduction — community reports describe halving the per-injection dose when site reactions are intrusive, then re-evaluating at 2 weeks.

SS-31 mechanism diagram

Core Supplies for This Protocol

The essentials for running any reconstituted injectable: cold storage, accurate syringes, alcohol prep pads, and metabolic tracking.

Cooluli Classic 4L Mini Fridge
Storage

Cooluli Classic 4L Mini Fridge

Compact thermoelectric mini-fridge with heat/cool toggle. The most-mentioned dedicated peptide-storage fridge in research community sources — fits ~20 vials and runs quietly.

View on Amazon →
BD Ultra-Fine 31G 0.3cc 5/16" Insulin Syringes (Box of 90)
Injection

BD Ultra-Fine 31G 0.3cc 5/16" Insulin Syringes (Box of 90)

0.3cc 31G syringes — each gradation marks 1 unit (vs 2 units on 1cc), making sub-50-unit peptide doses accurate. BD Ultra-Fine is the most widely-cited brand in peptide community sources.

View on Amazon →
Med-Pride Alcohol Prep Pads — Medical-Grade, Individually Wrapped
Injection

Med-Pride Alcohol Prep Pads — Medical-Grade, Individually Wrapped

Medical-grade 70% isopropyl alcohol prep pads, individually wrapped and sterile single-use. Standard for cleaning vial stoppers and injection sites before sub-Q dosing.

View on Amazon →
CONTOUR NEXT GEN Glucose Meter All-In-One Kit
Tracking

CONTOUR NEXT GEN Glucose Meter All-In-One Kit

Ascensia's CONTOUR NEXT GEN — the most clinically-validated home glucose meter. Includes 20 test strips + lancing device. Tracks the blood-sugar response GLP-1 users care about, especially during dose escalation.

View on Amazon →

As an Amazon Associate, The Peptide Catalog earns from qualifying purchases.

Full catalog →

Frequently Asked Questions

What side effects did SS-31 (elamipretide) trials report?
Phase 2 and Phase 3 trials in primary mitochondrial myopathy and Barth syndrome reported injection-site reactions as the dominant adverse event, with most events mild to moderate (Karaa et al., PMID 32096613; Karaa et al., PMID 37268435; Reid Thompson et al., PMID 33077895).
Is elamipretide FDA-approved?
Elamipretide received FDA approval in September 2025 for Barth syndrome under the brand name FORZINITY. Research-peptide and compounded forms are not FDA-approved. Trial safety data is the most informed source for adverse-event expectations.
How does the SS-31 injection-site reaction pattern compare to other peptides?
Trial reports describe SS-31 injection-site reactions as more frequent than most research peptides — reported in 80% of participants on elamipretide in MMPOWER-2, the majority mild (Karaa et al., PMID 32096613). In the TAZPOWER crossover, all 12 participants had injection-site erythema while on elamipretide versus 3 of 12 on placebo (Reid Thompson et al., PMID 33077895). Site rotation is the most-cited mitigation.
Are there cardiovascular concerns with SS-31?
The published MMPOWER-3 and TAZPOWER reports did not describe a cardiovascular adverse-event signal; serious adverse events were infrequent and were not deemed treatment-related (Karaa et al., PMID 37268435; Reid Thompson et al., PMID 33077895). The peptide's mechanism — cardiolipin stabilization in the inner mitochondrial membrane — is broadly protective in cardiac models.
When do trial protocols pause or stop SS-31?
Trial protocols allowed treatment to be withdrawn for adverse events. In the MMPOWER-3 Phase 3 trial, adverse events led to discontinuation in 7.3% of elamipretide participants versus 1.8% on placebo (Karaa et al., PMID 37268435).

References

Citation Topic PMID
Karaa et al., J Cachexia Sarcopenia Muscle (2020) MMPOWER-2 randomized crossover trial of elamipretide in primary mitochondrial myopathy 32096613
Karaa et al., Neurology (2023) MMPOWER-3 Phase 3 randomized trial of elamipretide in primary mitochondrial myopathy 37268435
Reid Thompson et al., Genet Med (2021) TAZPOWER Phase 2/3 elamipretide trial in Barth syndrome 33077895
Chavez et al., PNAS (2020) SS-31 mitochondrial protein interaction landscape 32554501

For educational and research purposes only. This is not medical advice. Research-peptide and compounded SS-31 outside the FDA-approved Barth indication are not FDA-approved. Consult a healthcare provider before use.